294 related articles for article (PubMed ID: 29987759)
1. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
[TBL] [Abstract][Full Text] [Related]
2. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
3. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
Holtorf AP; Gialama F; Wijaya KE; Kaló Z
Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
[TBL] [Abstract][Full Text] [Related]
4. Tendering and biosimilars: what role for value-added services?
Simoens S; Cheung R
J Mark Access Health Policy; 2020; 8(1):1705120. PubMed ID: 32002174
[No Abstract] [Full Text] [Related]
5. Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country.
Milovanovic DR; Pavlovic R; Folic M; Jankovic SM
Eur J Clin Pharmacol; 2004 May; 60(3):149-53. PubMed ID: 15057496
[TBL] [Abstract][Full Text] [Related]
6. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
7. A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.
Németh G; Mágó ML; Kaló Z; Lám J; Balogh T; Brodszky V
Front Med (Lausanne); 2023; 10():1282698. PubMed ID: 37964880
[TBL] [Abstract][Full Text] [Related]
8. How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders.
Miller FA; Lehoux P; Peacock S; Rac VE; Neukomm J; Barg C; Bytautas JP; Krahn M
Int J Technol Assess Health Care; 2019 Jan; 35(1):50-55. PubMed ID: 30732667
[TBL] [Abstract][Full Text] [Related]
9. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
10. Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.
Ehlers LH; Jensen MB; Schack H
J Pharm Policy Pract; 2022 Oct; 15(1):69. PubMed ID: 36273196
[TBL] [Abstract][Full Text] [Related]
11. Pricing of HPV vaccines in European tender-based settings.
Qendri V; Bogaards JA; Berkhof J
Eur J Health Econ; 2019 Mar; 20(2):271-280. PubMed ID: 30051152
[TBL] [Abstract][Full Text] [Related]
12. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
Inotai A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
[No Abstract] [Full Text] [Related]
13. A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt.
Elezbawy B; Fasseeh AN; Sedrak A; Eldessouki R; Gamal M; Eldebeiky M; Amer H; Akeel S; Morsy A; Amin A; Shafik A; Abaza S; Kaló Z
J Pharm Policy Pract; 2022 Mar; 15(1):10. PubMed ID: 35232487
[TBL] [Abstract][Full Text] [Related]
14. What can the Canadians and Americans learn from each other's health care systems?
Weil TP
Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
[TBL] [Abstract][Full Text] [Related]
15. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
Maniadakis N; Kourlaba G; Shen J; Holtorf A
BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
[TBL] [Abstract][Full Text] [Related]
17. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?
Dylst P; Vulto A; Simoens S
Health Policy; 2011 Jul; 101(2):146-52. PubMed ID: 21511353
[TBL] [Abstract][Full Text] [Related]
18. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
19. Pricing of HPV tests in Italian tender-based settings.
Inturrisi F; Berkhof J
J Med Econ; 2022; 25(1):762-768. PubMed ID: 35616231
[TBL] [Abstract][Full Text] [Related]
20. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
Kirschenbaum BE
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
